$0.44
0.00 (-0.23%)
Open$0.43
Previous Close$0.44
Day High$0.50
Day Low$0.41
52W High$2.48
52W Low$0.18
Volume—
Avg Volume1.31M
Market Cap8.40M
P/E Ratio—
EPS$-1.20
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+961.2% upside
Current
$0.44
$0.44
Target
$4.68
$4.68
$2.81
$4.68 avg
$5.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 18.76M | 19.22M | 3.13M |
| Net Income | -15,065,737 | -13,894,008 | -134,676 |
| Profit Margin | -80.3% | -76.3% | -4.3% |
| EBITDA | -11,014,205 | -10,721,892 | -218,349 |
| Free Cash Flow | — | — | -122,296 |
| Rev Growth | -2.4% | -2.4% | +0.4% |
| Debt/Equity | — | — | 0.21 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $254.31 | +0.38% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $360.55 | +0.62% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.33 | -1.21% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $499.65 | +1.69% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $631.81 | -0.17% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $293.52 | +0.74% | 69.3 | 39.97B |